** Brokerage H.C. Wainwright starts coverage on drugmaker Ionis Pharmaceuticals IONS.O with "buy" rating and a PT of $45
** Brokerage sees upside in IONS' pending commercial launches, including Tryngolza for lowering triglycerides and Wainua for transthyretin-mediated amyloidosis (ATTR)
** Brokerage estimates that Tryngolza could serve 2.3 million patients in the U.S. and become a growth driver for the company, potentially generating $1.8 billion in sales by 2033
** 17 out of 26 brokerages rate the stock "buy" or higher, 8 rate "hold" and 1 rate "sell" and their median PT is $60 as per LSEG data
** As of last close, IONS stock down 22.5% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。